Tvardi Therapeutics Inc., a Houston, TX-based clinical-stage biopharmaceutical company focused on the development of STAT3 inhibitors, raised over $5m in non-dilutive grants.
The three National Cancer Institute (NCI) funding awards are two Specialized Programs of Research Excellence (SPORE) grants to support clinical trials of TTI-101 in hepatocellular carcinoma (HCC) and gastrointestinal cancer as well as funding from the PREVENT program to support translational work of TTI-101 in HCC prevention.
The company intends to use the funds for the ongoing validation and clinical development of its lead compound, TTI-101. The new funding brings the total non-dilutive support of TTI-101 to approximately $20 million from multiple sources including the National Institutes of Health (NIH), V Foundation and the Cancer Prevention & Research Institute of Texas (CPRIT).
Led by Ronald DePinho, M.D., Co-Founder and Director, and Imran Alibhai, Ph.D., CEO, Tvardi Therapeutics is a clinical-stage biopharmaceutical company developing small molecule inhibitors of STAT3. STAT3 is a key regulatory protein positioned at the intersection of many signaling pathways integral to the survival and immune evasion of cancer cells as well as to the pathogenesis of many inflammatory and fibrotic diseases.
FinSMEs
26/07/2020